GSK plc (formerly GlaxoSmithKline), one of the world’s largest pharmaceutical and biotechnology companies, was founded in 2000 through a merger of Glaxo Wellcome and SmithKline Beecham in London, England. Dame Emma Walmsley led GSK as Chief Executive Officer from April 2017 to December 2025, making her the first woman ever to run a major global pharmaceutical company. Appointed after 17 years at L’Oréal and a successful tenure heading GSK’s Consumer Healthcare division, Walmsley transformed GSK into a focused biopharma powerhouse — most notably engineering the 2022 demerger of the consumer healthcare arm into Haleon plc, reinvigorating R&D with 15 major pipeline opportunities, and growing annual turnover to over £31 billion. She was appointed Dame Commander of the Order of the British Empire (DBE) in 2020 for services to the pharmaceutical industry.

(Suggested: Pfizer CEO Email & Net Worth – Albert Bourla Salary)

Dame Emma Walmsley – Quick Facts

GSK Competitors

GSK plc operates in the highly competitive global pharmaceutical, biotechnology, and vaccines industry. The key competitors of GSK include:

• AstraZeneca – Anglo-Swedish pharma giant; leader in oncology and respiratory
• Pfizer – US pharma leader in vaccines, oncology, and rare diseases
• Novartis – Swiss pharmaceutical company; strong in innovative medicines
• Roche – Swiss leader in oncology and diagnostics
• Sanofi – French pharma group; vaccines and specialty care
• Merck & Co. – US pharma giant; Keytruda and Gardasil powerhouse
• Eli Lilly – US pharma; diabetes, oncology, and neuroscience
• Bristol Myers Squibb – US biopharma; cardiovascular and immunology

Emma Walmsley Net Worth 2026 – GSK CEO Salary

As of 2026, Dame Emma Walmsley’s net worth is estimated at approximately $85–100 million USD, based on her disclosed GSK shareholdings, accumulated compensation over nearly nine years as CEO, long-term incentive plan payouts, and dividends. Walmsley’s wealth is primarily tied to her GSK stock holdings and options, combined with board fees from Microsoft Corporation where she has served as an independent director since 2019.

GSK CEO Compensation Breakdown (FY2024)

According to GSK’s 2024 Annual Remuneration Report, Emma Walmsley received total remuneration of £10.6 million ($13.3 million) for the fiscal year 2024. Only 16% of her compensation was attributable to base salary, with the remaining 84% tied to performance-based components.

GSK Net Worth 2026 – Is GSK Profitable?

Yes, GSK plc is a highly profitable company. Under Emma Walmsley’s final full year as CEO, GSK reported revenue of £31.4 billion and maintained strong growth in its specialty medicines and vaccines portfolio. As of February 2026, GSK’s market capitalization stands at approximately $120–123 billion USD, reflecting a 43% increase over the course of 2025.

GSK Financial Summary (FY2024)

(Recommended: AstraZeneca CEO Email & Net Worth – Pascal Soriot Salary)

GSK CEO Email Address | Emma Walmsley Contact

Below are the contact details and social media profiles for former GSK CEO Dame Emma Walmsley:

Career & Education – Company, University, & College

Dame Emma Walmsley’s career spans more than three decades across consumer goods and pharmaceuticals, beginning with 17 years at L’Oréal before she transitioned to GSK and ultimately became the first woman to lead a major pharmaceutical company.

Emma Walmsley Career Timeline

Walmsley began her career at L’Oréal where she spent 17 years in a variety of general management and marketing roles across Paris, London, and New York, including serving as General Manager of Garnier-Maybelline. In 2007, she was promoted to General Manager of Consumer Products for L’Oréal China, relocating to Shanghai to lead operations across global brands including Maybelline, Garnier, and L’Oréal Paris.

In May 2010, Walmsley joined GSK as President of Consumer Healthcare Europe. She rose quickly to head the global consumer healthcare division in October 2011, overseeing brands like Sensodyne, Voltaren, and Panadol. By March 2015, she was named CEO of Consumer Healthcare, a joint venture with Pfizer that would eventually become Haleon plc in 2022.

(Related: Novartis CEO Email & Net Worth – Vas Narasimhan Salary)

Walmsley was appointed Chief Executive Officer of GSK in April 2017, succeeding Sir Andrew Witty. During her nearly nine-year tenure, she executed a comprehensive transformation: spinning off the consumer healthcare arm into Haleon plc in July 2022 (the largest London IPO in over a decade at ~£30 billion), refocusing GSK on specialty medicines and vaccines, reinvigorating R&D with 15 major pipeline opportunities for launch between 2025 and 2031, and growing key products like Shingrix (shingles vaccine, £4.3B+ annual sales), Arexvy (RSV vaccine), and Jemperli (oncology). In September 2025, GSK announced her departure effective December 31, 2025, with Luke Miels succeeding her as CEO from January 2026.

Education

Emma Walmsley Wiki – Age, Husband, Family, & More

Dame Emma Walmsley (age 56, born June 1969) was born in Barrow-in-Furness, Lancashire (now Cumbria), England. She is the daughter of Vice-Admiral Sir Robert Walmsley KCB, a senior officer in the Royal Navy, and Lady Christina V. Walmsley (née Melvill). Emma married David Owen, an entrepreneur, in September 1995 in Greenwich, London. The couple have four children together.

Walmsley was appointed Dame Commander of the Order of the British Empire (DBE) in the 2020 Birthday Honours for services to the pharmaceutical industry and business, making her Dame Emma Walmsley. She has served on the Microsoft Corporation board of directors as an independent non-executive director since September 2019.

Notable Achievements & Recognitions

• First Female CEO of a Major Pharma Company – Appointed GSK CEO in April 2017, a historic first in the global pharmaceutical industry
• Dame Commander of the British Empire (DBE) – Awarded in the 2020 Birthday Honours for services to pharmaceuticals
• Fortune Most Powerful Women – Ranked #7 on Fortune’s “100 Most Powerful Women” list (2023)
• Forbes Most Powerful Women – Ranked #15 on Forbes’ “World’s 100 Most Powerful Women” (2023)
• Haleon Demerger Architect – Engineered the 2022 spin-off of GSK Consumer Healthcare into Haleon plc, the largest London IPO in over a decade
• Microsoft Board Director – Independent non-executive director since September 2019
• Fortune Most Powerful International Women – Topped the list in 2018; ranked #2 in 2019

Outside of her professional life, Walmsley is known for her focus on talent development, personable leadership style, and passion for innovation. She enjoys yoga and has spoken publicly about the importance of work-life balance.

(Suggested: Eli Lilly CEO Email & Net Worth – Dave Ricks Salary)

About GSK

GSK plc (formerly GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company headquartered at 79 New Oxford Street, London. The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, though its roots trace back to companies like Glaxo (1873), Burroughs Wellcome (1880), and Smith, Kline & Company (1830).

GSK trades on both the London Stock Exchange (LSE: GSK) and the New York Stock Exchange (NYSE: GSK). The company employs approximately 69,000 people worldwide and operates in over 100 countries. In July 2022, GSK demerged its consumer healthcare business to form Haleon plc (LSE: HLN), which now operates independently with brands like Sensodyne, Panadol, and Voltaren. Under Walmsley’s leadership, GSK plans to launch more than 20 new products by 2026, with at least 10 having blockbuster potential.

Frequently Asked Questions (FAQ)

Who is the current CEO of GSK?

The current CEO of GSK is Luke Miels, who took over from Dame Emma Walmsley on January 1, 2026. Miels had served as GSK’s Chief Commercial Officer since 2017, managing its global medicines and vaccines portfolio across over 100 countries.

What is Emma Walmsley’s net worth in 2026?

As of 2026, Dame Emma Walmsley’s net worth is estimated at $85–100 million USD, primarily based on accumulated GSK compensation, stock holdings, LTIP payouts, dividends, and her Microsoft board director fees. Her GSK total remuneration in 2024 was £10.6 million ($13.3 million).

What was GSK CEO Emma Walmsley’s salary?

Emma Walmsley’s total compensation for fiscal year 2024 was approximately £10.6 million (~$13.3 million), comprising a £1.3 million base salary, annual bonus, long-term incentive payouts, and benefits. Only 16% of her pay was base salary, with the rest tied to performance targets. In 2023, she earned £12.7 million ($16 million), a 51% increase from 2022.

What is GSK CEO’s email address?

The email address for former GSK CEO Emma Walmsley is [email protected]. She can also be found on LinkedIn. For the current CEO Luke Miels, visit the GSK CEO Luke Miels page.

Why did Emma Walmsley leave GSK?

In September 2025, GSK announced that Emma Walmsley would step down as CEO effective December 31, 2025. After nearly nine years leading GSK’s transformation — including the Haleon demerger, R&D reinvigoration, and strategic refocus on specialty medicines — Walmsley transitioned leadership to Luke Miels. She remains with GSK in an advisory capacity through September 2026 to support an orderly transition.

Is GSK a profitable company?

Yes, GSK is a highly profitable pharmaceutical company. In fiscal year 2024, GSK reported revenue of £31.4 billion (up 3.5%) and net income of £2.57 billion. While reported net income declined due to one-time charges, core operating performance remained strong. GSK’s market capitalization reached $120–123 billion by February 2026, and the company expects revenues to exceed £40 billion by 2031.

Article last updated:March 2026March 2, 2026